Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

Phase 1

Completed

Conditions: Growth Hormone Disorder
Adult Growth Hormone Deficiency

Interventions: Drug: somapacitan
Drug: Norditropin NordiFlex®

First Posted Date: 2012-10-15

Last Posted Date: 2020-12-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 35

Registration Number: NCT01706783

Locations: 🇸🇪
Novo Nordisk Investigational Site, Stockholm, Sweden

Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women

Phase 4

Completed

Conditions: Healthy
Menopause

Interventions: Drug: 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)

First Posted Date: 2012-10-12

Last Posted Date: 2017-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 191

Registration Number: NCT01705249

Locations: 🇸🇪
Novo Nordisk Investigational Site, Uddevalla, Sweden

Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic insulin aspart

First Posted Date: 2012-10-11

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 89

Registration Number: NCT01704378

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom

A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2012-10-11

Last Posted Date: 2016-12-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01704417

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Efficacy of Repaglinide in Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: repaglinide
Drug: glyburide
Drug: placebo

First Posted Date: 2012-10-03

Last Posted Date: 2017-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 9

Registration Number: NCT01698931

Locations: 🇮🇹
Novo Nordisk Investigational Site, Padova, Italy

Comparison of Two Insulin Aspart Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: insulin aspart

First Posted Date: 2012-10-03

Last Posted Date: 2017-03-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01698697

Locations: 🇿🇦
Novo Nordisk Investigational Site, Bloemfontein, South Africa

Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency

Phase 4

Terminated

Conditions: Adult Growth Hormone Deficiency
Growth Hormone Disorder

Interventions: Drug: somatropin

First Posted Date: 2012-10-03

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 7

Registration Number: NCT01698944

Locations: 🇬🇷
Novo Nordisk Investigational Site, Athens, Greece

Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Phase 2

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart 30
Drug: biphasic human insulin 30

First Posted Date: 2012-10-02

Last Posted Date: 2017-01-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 13

Registration Number: NCT01697618

Locations: 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom

Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation

Phase 4

Completed

Conditions: Foetal Growth Problem
Small for Gestational Age

Interventions: Drug: somatropin

First Posted Date: 2012-10-02

Last Posted Date: 2017-01-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 75

Registration Number: NCT01697644

Locations: 🇳🇱
Novo Nordisk Investigational Site, Rotterdam, Netherlands

Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart 30
Drug: insulin aspart

First Posted Date: 2012-10-02

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 131

Registration Number: NCT01697631

Locations: 🇵🇱
Novo Nordisk Investigational Site, Wroclaw, Poland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy